Everything You Need To Know About RSV This Fall
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that the United States National Institutes of Health ...